Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Core Viewpoint - Harrow, a leading provider of ophthalmic disease management solutions in North America, has announced a private offering of $250 million in senior unsecured notes due 2030, with an interest rate of 8.625% [1][2]. Group 1: Offering Details - The 2030 Notes will bear an interest rate of 8.625% per year, with interest payable semi-annually starting March 15, 2026, and maturing on September 15, 2030 [2]. - The offering price for the 2030 Notes is set at 100% of the principal amount [2]. - The offering is expected to close on September 12, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to repay a $107.5 million facility with Oaktree Fund Administration, redeem $75 million of outstanding 2026 Notes, and redeem $40.25 million of outstanding 2027 Notes [3]. - Remaining proceeds are anticipated to be allocated for general corporate purposes, including funding future strategic business development opportunities [3]. Group 3: Company Overview - Harrow, Inc. specializes in ophthalmic disease management solutions, offering a range of products for conditions such as dry eye disease, age-related macular degeneration, cataracts, and glaucoma [7]. - The company is committed to providing safe, effective, accessible, and affordable medications to enhance patient compliance and improve clinical outcomes [7].